Vaccine Candidate AZD1222 Effective Against COVID-19
A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.
Vaccines
Pfizer, BioNTech to Submit EUA Request for COVID-19 Vaccine Candidate
Pfizer and BioNTech will submit an Emergency Use Authorization (EUA) request to the FDA for their mRNA-based vaccine candidate BNT162b2 against COVID-19.
Final Analysis Reveals COVID-19 Vaccine Candidate BNT162b2 95% Effective
The analysis of the primary outcomes was based on 170 confirmed cases of COVID-19.
Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Near 95% Effective
The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.
MPR Weekly Dose Podcast Episode 58
Major developments in COVID-19 vaccine and antibody treatments: Are we close to having a vaccine gain Emergency Use Authorization? An NIH study concluded that hydroxychloroquine has no clinical benefit; And unrelated to COVID, but still big news, the Advisory Committee have voted on what would-be the first Alzheimer disease treatment in decades.
Phase 2/3 Trials of Plant-Derived COVID-19 Vaccine Begin
The adjuvanted coronavirus-like particle (CoVLP) COVID-19 is composed of recombinant spike (S) glycoprotein expressed as virus-like particles developed through plant-based vaccine technology.
Novavax COVID-19 Vaccine Candidate Fast Tracked
NVX-CoV2373 is engineered from the genetic sequence of severe acute respiratory syndrome coronavirus 2 using the recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein.
COVID-19 Vaccine Candidate More Than 90% Effective, Say Pfizer, BioNTech
The trial will continue as planned and final analysis is expected when the number of confirmed COVID-19 cases reaches 164.
FDA Identifies Most Needed Meds to Address Urgent Medical Conditions
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
COVID-19 Vaccine Allocation: Ethical Concerns, Practical Challenges
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
